Use of mesna prophylaxis in patients with cyclophosphamide-treated ANCA-associated vasculitis: cross-sectional survey of practitioners.

Lukas JoosSolange Gonzalez ChiappeThomas NeumannAlfred Daniel Mahr

Published in: Rheumatology international (2024)

Systematic co-prescription of mesna is the prevailing practice for CYC treatments for AAV. The practice seems to involve practicability considerations and differs between generations.

Keyphrases

primary care
healthcare
quality improvement
low dose
high dose
gene therapy